Evidence map›Paper›PMID 26320827›Full record

Trial reportDrug and alcohol dependence2015

A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Kyle M Kampman, Kevin G Lynch, Helen M Pettinati, Kelly Spratt, Michael R Wierzbicki, Charles Dackis, Charles P O'Brien

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Open-label pilot study of lisdexamfetamine for cocaine use disorder.The American journal of drug and alcohol abuse · 2021
    Trial
  8. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kyle M KampmanDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA. Electronic address: kampman@upenn.edu.
Kevin G LynchDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA.
Helen M PettinatiDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA.
Kelly SprattDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Michael R WierzbickiCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Charles DackisDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA.
Charles P O'BrienDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA.
University of Pennsylvania · US

Funding

TREATMENT STRATEGIES FOR METHODONE NONRESPONDERSP60DA005186 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI O'BRIEN, CHARLES P · 1997 to 2012
$28.1M
Two Medications to Treat Cocaine and Alcohol DependenceP50DA012756 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI KAMPMAN, KYLE MATTHEW · 1999 to 2013
$17.4M
Center for the Development of Novel Medications for Cocaine DependenceU54DA039002 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI KAMPMAN, KYLE MATTHEW · 2014 to 2018
$5.1M
Mental Health Biostatistics Training ProgramT32MH065218 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BILKER, WARREN B. · 2003 to 2018
$1.3M
NIDA NIH HHS P50 DA012756NIDA NIH HHS P60 DA005186NIDA NIH HHS P60-DA-05186-17NIDA NIH HHS U54 DA039002NIMH NIH HHS T32 MH065218
6 · The paper itself

Abstract

backgroundModafinil is a medication approved for narcolepsy and shift work sleep disorder. It has both dopaminergic and glutamatergic activity that could be useful for the treatment of cocaine dependence. Modafinil has reduced cocaine subjective effects and cocaine self-administration in human laboratory trials and has reduced cocaine use in cocaine dependent patients in some clinical trials.

methodsThis was an 8-week, double blind, placebo controlled clinical trial involving 94 cocaine dependent subjects. Subjects received 300mg of modafinil or identical placebo daily along with weekly individual therapy. The primary outcome measure was cocaine use measured by self-report, and confirmed by twice weekly urine benzoylecgonine tests (UBT). Additional outcome measures included cocaine craving measured by the Brief Substance Craving Scale and global improvement measured by the Clinical Global Impression Scale (CGI).

resultsThe odds ratio (OR) in favor of abstinence for modafinil vs. placebo was 2.54 (p=. 03) and modafinil-treated subjects were significantly more likely than placebo-treated subjects to be abstinent from cocaine during the last 3 weeks of the trial, 23% vs. 9%, χ(2)=3.9, p<.05. Modafinil treated subjects were more likely to report very low levels of cocaine craving intensity and duration on the Brief Substance Craving Scale (OR=2.04, p=.03 and OR 1.06, p=.03 respectively). Modafinil-treated subjects were also more likely than placebo-treated subjects to rate themselves as "very much improved" on the CGI (OR=2.69, p=.03).

conclusionModafinil may be an efficacious treatment for cocaine dependence.

Indexed as

AdolescentAdultAlcoholismBenzhydryl CompoundsCocaineCocaine-Related DisordersCognitive Behavioral TherapyCombined Modality TherapyCravingDouble-Blind MethodDrug MonitoringFemaleHumansMaleMiddle AgedModafinilBenzhydryl CompoundsbenzoylecgonineCocaineModafinilAlcoholClinical trialCocaineModafinilPlacebo

Identifiers

PMID26320827
PMCPMC4582003
OpenAlexW1806449367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.